On Nov 14, major Wall Street analysts update their ratings for $Corvus Pharmaceuticals (CRVS.US)$, with price targets ranging from $13 to $24.
Jefferies analyst Roger Song initiates coverage with a buy rating, and sets the target price at $13.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
Oppenheimer analyst Jeff Jones maintains with a buy rating, and adjusts the target price from $8 to $14.
Ladenburg Thalmann analyst Aydin Huseynov maintains with a buy rating, and adjusts the target price from $21 to $24.
Furthermore, according to the comprehensive report, the opinions of $Corvus Pharmaceuticals (CRVS.US)$'s main analysts recently are as follows:
Anticipation is building for the upcoming report of Phase 1 interim data from soquelitinib in atopic dermatitis scheduled for December. The early data from the initial doses may furnish clinical proof of concept for the oral ITK inhibitor's potential in a wider range of inflammation and immunology applications.
Following the company's quarterly results, there is a positive outlook for the upcoming atopic dermatitis readout expected in December, illustrated by management's enthusiasm. Despite a constrained cash situation due to the level of clinical activity, the company reported having sufficient funds to continue operations into early 2026.
Here are the latest investment ratings and price targets for $Corvus Pharmaceuticals (CRVS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月14日，多家華爾街大行更新了$Corvus Pharmaceuticals (CRVS.US)$的評級，目標價介於13美元至24美元。
富瑞集團分析師Roger Song首次給予買入評級，目標價13美元。
瑞穗證券分析師Graig Suvannavejh維持買入評級。
奧本海默控股分析師Jeff Jones維持買入評級，並將目標價從8美元上調至14美元。
Ladenburg Thalmann分析師Aydin Huseynov維持買入評級，並將目標價從21美元上調至24美元。
此外，綜合報道，$Corvus Pharmaceuticals (CRVS.US)$近期主要分析師觀點如下：
以下爲今日4位分析師對$Corvus Pharmaceuticals (CRVS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
